Toragen, Inc. Announced Positive Safety Data Update from Cohort 2 and the Initiation of its Dose Expansion of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer
Toragen Announced Positive Safety Update from Cohort 1 of its Phase 1 Trial
Toragen, Inc. Announced Full Enrollment of Cohort 1 of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer
SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, today announced that it has initiated a Phase 1 clinical trial to evaluate its first drug candidate (TGN-S11). It is believed that HPV survives within the cells and can eventually cause cancer by blocking immune responses and going undetected by the immune system. Toragen’s drug candidate, TGN-S11, inhibits the E5 oncogene of HPV in pre-clinical studies. Toragen believes this will allow the HPV-infected cancer cells to be detected by killer T-cells which could trigger an immune response that could be beneficial in cancer treatment.
Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers
Toragen, Inc. Announces Appointment of Chief Scientific Officer